Lilly(Eli) & Co

-0.07 (-0.03%)
4:42:11 PM EDT: $243.17 +0.11 (+0.05%)
Products, Regulatory

ASPR Pauses Allocation Of Bamlanivimab And Etesevimab Together, Etesevimab Alone, And Regen-Cov

Published: 12/23/2021 17:28 GMT
Lilly(Eli) & Co (LLY) - :aspr Pauses Allocation of Bamlanivimab and Etesevimab Together, Etesevimab Alone, and Regen-cov.
Data Show That It is Unlikely That Bamlanivimab and Etesevimab Administered Together Or Regen-cov Will Retain Activity Against Omicron Variant.
Based on Similar Cell Culture Data Currently Available, Sotrovimab Appears to Retain Activity Against the Omicron Variant.
An Additional 300,000 Doses of Sotrovimab Will Be Available for Distribution in January.
Shipments of Sotrovimab Did Resume This Week, and Delivery of 55,000 Doses of Product Has Begun.
Further Company Coverage: Llyn ((reuters.